Invitris

Private

MunichHealthcare & Life Scienceshttps://www.invitris.com/

Last Round

Grant

Feb 17, 2025

Est. Valuation

$1.79M

Total Funding Raised

$3.34M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Invitris is a biotechnology company that develops a cell-free protein expression platform called Phactory™ to manufacture therapeutic proteins, including bacteriophages, to combat antibiotic-resistant infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

cell-free protein synthesissynthetic biologyprotein engineeringbacteriophage developmentantimicrobial resistancephage therapydrug discovery platformbiotech infrastructurehigh-throughput screeningcomputational protein designendolysinprotein expressionlab-on-a-chipbiomanufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Invitris Comps

Public and private peers based on sector, stage, and business model.

Invitris comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Invitris Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Feb 17, 2025
Accelerator	Dec 19, 2024
Grant	May 9, 2023
Accelerator	Mar 10, 2023
Grant	Jan 27, 2022

View all Funding Rounds

Key People

Founding team and executive leadership

Patrick Grossmann

CEO Co-Founder

Founding Team

Invitris Investors

Notable investors and investment history

Invitris investors
Investor	Rounds
European Innovation Council Fund	Accelerator, Grant
INCATE	Grant
Y Combinator	Accelerator
another.vc	Accelerator
10x Founders	Accelerator
Mergus Ventures	Accelerator

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 16, 2026
Monthly visitors increased 1403% from 61 to 917.

View all signals

Invitris Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Invitris Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Invitris's valuation, stock price, and market status.

Firmographic Details

HeadquartersMunich

Employee Range21

Year Founded2018

Last FundingFeb 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.